ReviewJournal of hepatology2016
Sarcopenia from mechanism to diagnosis and treatment in liver disease.
Review in Journal of hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 302 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
HMB for Denutrition in Patients With Cirrhosis (HEPATIC)
Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis- Child C: A Randomized Double Blind Control Trial
Effect of Sarcopenia on the Efficacy and Prognosis of HCC Treated With Systemic Therapies
Building of Prognosis Model for Patients With Cirrhosis Based on Sarcopenia in Assessment With the Technology of Deep Learning
Who cites it
302 citing papers in PubMed, 11 syntheses or guidelines pooled it, 587 citations in OpenAlex.
- Can ammonia scavenging treat MASLD? Evaluating the evidence for L-ornithine L-aspartate-A systematic review.European journal of clinical investigation · 2026Pooled it
- Prognostic value of different sarcopenia assessment methods for mortality in patients with liver cirrhosis: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- The impact of sarcopenia and frailty on decompensation in compensated cirrhosis: A systematic review.Hepatology communications · 2025Pooled it
- Effect of sarcopenia on the survival of patients undergoing liver transplantation: a meta-analysis.Surgery today · 2025Pooled it
- The prognostic value of sarcopenia in acute-on-chronic liver failure: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Opportunistic computed tomography-based sarcopenia screening and mortality after liver transplantation: a systematic review and meta-analysis.Revista da Associacao Medica Brasileira (1992) · 2025Pooled it
- Effectiveness of Exercise Interventions on Body Composition, Exercise Capacity, Fatigue, and Quality of Life in Patients with Liver Cirrhosis: A Meta-Analysis of Randomized Controlled Trials.Digestive diseases and sciences · 2024Pooled it
- Association between sarcopenia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: a systematic review and meta-analysis.Abdominal radiology (New York) · 2024Pooled it
- Prognostic role of pretreatment skeletal muscle index in gastric cancer patients: A meta-analysis.Pathology oncology research : POR · 2023Pooled it
- Effects of Branched-Chain Amino Acids on Parameters Evaluating Sarcopenia in Liver Cirrhosis: Systematic Review and Meta-Analysis.Frontiers in nutrition · 2022Pooled it
- Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology (Baltimore, Md.) · 2021Guideline
- Rifaximin Improves Frailty in Patients with Decompensated Cirrhosis: A Randomized Trial.Digestive diseases and sciences · 2026Trial
- Elective Transjugular Intrahepatic Portosystemic Shunt Creation in Cirrhosis Improves Body Composition and Function: Pilot Randomized Trial.Cardiovascular and interventional radiology · 2026Trial
- The effect of a diet based on vegetable and dairy protein on biochemical and functional indicators of sarcopenia in patients with liver cirrhosis: a randomized controlled trial.Nutrition journal · 2025Trial
- Substitution of One Meat-Based Meal With Vegetarian and Vegan Alternatives Generates Lower Ammonia and Alters Metabolites in Cirrhosis: A Randomized Clinical Trial.Clinical and translational gastroenterology · 2024Trial
- A nomogram based on psoas muscle index predicting long-term cirrhosis incidence in non-cirrhotic patients with HBV-related acute‑on‑chronic liver failure.Scientific reports · 2023Trial
- Trial
- Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes.Scientific reports · 2022Trial
- Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia.Hepatology international · 2022Trial
- Trial
242 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Sarcopenia or loss of skeletal muscle mass is the major component of malnutrition and is a frequent complication in cirrhosis that adversely affects clinical outcomes. These include survival, quality of life, development of other complications and post liver transplantation survival. Radiological image analysis is currently utilized to diagnose sarcopenia in cirrhosis. Nutrient supplementation and physical activity are used to counter sarcopenia but have not been consistently effective because the underlying molecular and metabolic abnormalities persist or are not influenced by these treatments. Even though alterations in food intake, hypermetabolism, alterations in amino acid profiles, endotoxemia, accelerated starvation and decreased mobility may all contribute to sarcopenia in cirrhosis, hyperammonemia has recently gained attention as a possible mediator of the liver-muscle axis. Increased muscle ammonia causes: cataplerosis of α-ketoglutarate, increased transport of leucine in exchange for glutamine, impaired signaling by leucine, increased expression of myostatin (a transforming growth factor beta superfamily member) and an increased phosphorylation of eukaryotic initiation factor 2α. In addition, mitochondrial dysfunction, increased reactive oxygen species that decrease protein synthesis and increased autophagy mediated proteolysis, also play a role. These molecular and metabolic alterations may contribute to the anabolic resistance and inadequate response to nutrient supplementation in cirrhosis. Central and skeletal muscle fatigue contributes to impaired exercise capacity and responses. Use of proteins with low ammoniagenic potential, leucine enriched amino acid supplementation, long-term ammonia lowering strategies and a combination of resistance and endurance exercise to increase muscle mass and function may target the molecular abnormalities in the muscle. Strategies targeting endotoxemia and the gut microbiome need further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.